Cure Alzheimer's Fund Cure Alzheimer's Fund

Modulation of Abeta Assembly and Cytotoxicity by a Fragment of Myelin Basic Protein

2008

We have identified myelin basic protein (MBP) as a novel factor in brain that can bind Abeta and potently inhibit its assembly into fibrils. In light of this novel finding the overall hypothesis of this proposal is that defined fragments of MBP can regulate Abeta assembly and modulate its cytotoxic properties. This will provide the basis for developing novel and potent Abeta assembly inhibitors.

Studies of APP and Abeta Translational William Van Nostrand

Funding to Date

$100,000

Focus

Studies of APP and Abeta, Translational

Researchers

William Van Nostrand, Ph.D.

Related Content:


ADAM10 Cleavage of Amyloid Precursor Protein: Physiological Function in the Brain and Therapeutic Potential for Alzheimer’s Disease Jaehong Suh, Ph.D. 2024-02-01 APP Gene Dose-Mediated Dysregulation of the Endolysosomal Network Acts to Compromise Synaptic Structure and Function Leading to Alzheimer’s Disease in Down Syndrome William C. Mobley 2023-12-21 Role of Stabilization of MAMs and MAM-Associated Palmitoylated APP (MAM-palAPP) in Alzheimer’s Disease Raja Bhattacharyya 2023-11-02 Effect of APOE Genotype in a Novel Rat Model of Cerebral Amyloid Angiopathy William Van Nostrand 2023-03-21 Structural Mimicry in Microbial and Antimicrobial Amyloids Connected to Neurodegenerative Diseases Meytal Landau 2023-01-20 Effects of Depalmitoylation and ACAT Inhibition on Axonal Amyloid Beta Generation Via MAM-Associated palAPP Raja Bhattacharyya Rudy Tanzi 2022-02-10 The NEDD4-1 and PKCa Connection in Alzheimer’s Disease Gentry Patrick 2020-11-05 SFRP1 as a Therapeutic Target and Diagnostic/Prognostic Factor in Alzheimer’s Disease Paola Bovolenta Pilar Esteve 2020-11-04